Ziopharm in Partner Talks for Experimental Cancer Drug

Ziopharm Oncology Inc., a developer of experimental cancer drugs, is in talks with potential partners to market its lead compound, palifosfamide, Chief Executive Officer Jonathan Lewis said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.